Former world number one Ratchanok Intanon landed a crucial victory over Indian star PV Sindhu at badminton's World Tour Finals in Bangkok on Thursday.
It was a double victory for Thailand's hopes, as 13th-seed Pornpawee Chochuwong also booked a semi-final spot after a shock win over Taiwanese top-ranked Tai Tzu-ying.
Intanon trailed for most of the first game against Sindhu, but showed a ballerina's footwork and killer instinct to take it 21-18.
The 25-year-old Thai claimed the match taking the second game 21-13.
"I just want to keep going and focus on winning, point-by-point," Intanon said afterwards.
"It wasn’t my day," said Sindhu.
"Losing the first game made the difference. My timing was a bit off, so a bit disappointed."
Both players were coming off an initial loss in the round-robin tournament; Tai beat Sindhu, the Rio Olympics silver medallist, in a three-game thriller on Wednesday.
Chochuwong upset fifth seed Intanon in three games on Wednesday.
On Thursday, Chochuwong, 22, went into her match having never won a game against Tai in previous encounters, but won 21-17, 21-11 in 37 minutes.
Earlier, Carolina Marin -- looking for a hat-trick of titles -- marched towards a swift victory over Canada's tenth-ranked Michelle Li 21-16, 21-13.
"I think I keep getting better and better," Marin said.
In the men's singles, Taiwan's 12th-ranked Wang Tzu-wei was victorious over India's 14th-seed Srikanth Kidambi in a three-game match that lasted 78 minutes, finishing 19-21, 21-9, 21-19.
The delayed 2020 season finale is the third tournament behind closed doors in three weeks in Bangkok, as badminton resumes after months of coronavirus cancellations.
The top eight players in all singles and doubles disciplines are contesting this week's tournament, but China and Japan are absent because of coronavirus problems.
Despite the strict biosecurity arrangements, four people inside the tournament "bubble" have tested positive, including two players who were forced to withdraw.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.